Related Experiment Video

Updated: Apr 25, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

20.3K

Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment

Marion T Weigel1, Katrin Rath, Ibrahim Alkatout

  • 1Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Oncology
|August 14, 2014
PubMed
Abstract

Insights

Nilotinib shows promise in treating ovarian cancer by inhibiting cell growth and migration. This tyrosine kinase inhibitor may offer a new targeted therapy option, especially when combined with standard chemotherapy drugs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Nilotinib is a tyrosine kinase inhibitor targeting c-Kit, Abl, and PDGF receptors.
  • Ovarian cancer remains a significant health challenge with a need for novel therapeutic strategies.

Purpose of the Study:

  • To investigate the preclinical efficacy of nilotinib in human ovarian cancer cell lines.
  • To assess nilotinib's activity based on varying tyrosine kinase expression patterns.

Main Methods:

  • Ovarian cancer cell lines were treated with nilotinib alone and in combination with carboplatin and paclitaxel.
  • Cell growth inhibition, apoptosis induction (TUNEL assay), and cell migration were evaluated.

Main Results:

  • Nilotinib significantly inhibited cell growth in PDGFR-α-positive ovarian cancer cell lines.
  • Combinations of nilotinib with carboplatin and paclitaxel demonstrated synergistic effects on proliferation and apoptosis.
  • Nilotinib reduced cell migration, both alone and in combination treatments.

Conclusions:

  • Nilotinib exhibits preclinical activity against ovarian cancer cells.
  • The combination therapy showed enhanced efficacy, suggesting a potential role for nilotinib in ovarian cancer treatment.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

13.8K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K